Bristol-Myers Squibb Company (BMY) : Mondays money flow points at investors jumping to buy the stock on the weakness of price. $55.91 million worth of transactions were on upticks, whereas, the downticks accounted for $41.9 million worth of transactions. The net money flow was a positive $14.01 million and the uptick to downtick ratio was 1.33. However, the block trades showed a clear dominance of the bulls with a very healthy ratio of 3.32 in their favor. The net money flow into the stock was $14.44 million. The value of block trades done on downticks was only $6.22 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $20.67 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Bristol-Myers Squibb Company (BMY) was trading at $75.96, down $0.04 during day. The stock slid -0.05% over the previous days close. For the week, the stock recorded 0.9% over the previous weeks close.
Bristol-Myers Squibb Company is up 10.9% in the last 3-month period. Year-to-Date the stock performance stands at 11.67%. Shares of Bristol-Myers Squibb Company rose by 0.76% in the last five trading days and 6.46% for the last 4 weeks. In a related news, The director, of Bristol Myers Squibb Co, Andreotti Lamberto had unloaded 23,200 shares at $74.65 per share in a transaction on July 7, 2016. The total value of transaction was $1,731,880. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Bristol-Myers Squibb Company (NYSE:BMY): On Mondays trading session , Opening price of the stock was $76.27 with an intraday high of $76.36. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $75.62. However, the stock managed to close at $75.96, a loss of 0.05% for the day. On the previous day, the stock had closed at $76. The total traded volume of the day was 3,794,127 shares.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.